According to the information released by the State Drug Administration on January 26, Smeglutide tablets under Novo Nordisk (China) Pharmaceutical Co., Ltd. have been approved for marketing to treat type 2 diabetes. This is the first domestically approved oral GLP-1 (glucagon like peptide-1) receptor agonist.
According to the data, Novo Nordisk's smeglutide injection has been approved for the treatment of type 2 diabetes in China, and other GLP-1 drugs in China are also approved for injection. In addition, Smegglutide is known as the "miracle drug for weight loss" due to its good effect on weight loss.